Clara Noemi Sivisaca Bonifaz

Clara Noemi Sivisaca Bonifaz

Auto-generated profile, based on publicly available information

Clara Noemi Sivisaca Bonifaz

Ministerio de Salud Púbica, Ecuador

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in Ibero-American Journal of Health Science Research
Verified
Journal Article
Open access
PDF file
AAAna Gabriela Aillón Albán
Ana Gabriela Aillón Albán
FNFernanda De Las Mercedes López Naveda
Fernanda De Las Mercedes López Naveda
ICIrina Talia Guzmán Chávez
Irina Talia Guzmán Chávez
AAAndrea Carolina Arregui Ayala
Andrea Carolina Arregui Ayala
CBClara Noemi Sivisaca Bonifaz
Clara Noemi Sivisaca Bonifaz
Combination therapy with immune checkpoint inhibitors, specifically CTLA-4 and PD-1 blockade, has shown promise in treating advanced melanoma. However, this approach often results in increased toxicity, necessitating a careful evaluation of both efficacy and safety. This review explores clinical outcomes, survival rates, and adverse events associated with these therapies. A systematic review of PubMed, Scopus, and clinical trial databases was conducted for studies published from 2014 to 2024. Studies assessing the combined use of CTLA-4 and PD-1 inhibitors in melanoma patients were included, focusing on overall survival (OS), progression-free survival (PFS), and treatment-related adverse events (AEs). The combination of CTLA-4 and PD-1 inhibitors significantly improved clinical outcomes in advanced melanoma. In trials like CheckMate 067, the five-year overall survival rate reached 52%, with a notable improvement in progression-free survival. However, these benefits came with substantial toxicity, as approximately 55% of patients experienced grade 3 or 4 treatment-related adverse events, including colitis, hepatitis, and pneumonitis. Despite these challenges, combination therapy led to durable responses in a subset of patients, underscoring its efficacy. The review emphasizes the need for balancing efficacy with toxicity management in clinical practice. While CTLA-4 and PD-1 inhibitor combinations improve survival in advanced melanoma, increased toxicity presents challenges. Further research is needed to optimize treatment strategies and enhance patient selection to balance efficacy and safety.